Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Regular use of selective COX-2 inhibitors decreases risk of breast cancer

30.01.2006


Regular use of selective COX-2 inhibitors significantly reduces the risk of breast cancer. A case-control study published today in the open access journal BMC Cancer observed that daily use of selective COX-2 inhibitors, including celecoxib (Celebrex) and rofecoxib (Vioxx), was associated with a 71% reduction in the risk of breast cancer. Non-selective COX-2 inhibitors, such as aspirin and ibuprofen, also reduced the risk of breast cancer. This study highlights the potential of nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention of breast cancer.



Randall Harris and colleagues from The Ohio State University College of Medicine and Public Health, Columbus, Ohio, USA, collected data on 323 patients with invasive breast cancer shortly after their diagnosis. Harris et al. matched the patients for age, race and county of residence with 649 control individuals with no personal history of cancer. Data collected for patients and controls included information on breast cancer risk factors, and the use of selective COX-2 inhibitors and other NSAIDs.

Harris et al.’s results show that selective COX-2 inhibitors, as a group, were associated with a significantly reduced risk of breast cancer (OR=0.29) when taken daily for at least two years: a daily dose of 200 mg celecoxib reduced the risk of breast cancer by 83% and a daily dose of 25 mg rofecoxib reduced the risk of breast cancer by 64%. Regular use of non-selective COX-2 inhibitors - aspirin (325 mg), ibuprofen (200mg) and naproxen (250 mg) – also significantly reduced the risk of breast cancer, but less so than regular intake of selective COX-2 inhibitors. Ibuprofen and aspirin significantly decreased the risk of developing breast cancer when taken at least every other day for at least five years. Regular intake of acetaminophen, an analgesic lacking COX-2 activity, had no effect on the risk of breast cancer.

Juliette Savin | alfa
Further information:
http://www.biomedcentral.com

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>